Targeted Microarray-Based Cell-Free DNA Test for 22q11.2 Deletion Undergoes Internal Analytical Verification
Background
22q11.2 deletion syndrome (DiGeorge syndrome) is a common genetic disorder linked to heart defects, immune problems, and developmental delays. Traditional prenatal diagnosis often involves invasive procedures like amniocentesis. Non-invasive prenatal testing (NIPT) using cell-free DNA (cfDNA) from maternal blood offers a safer alternative, but its accuracy for microdeletions like 22q11.2 requires rigorous validation. This work focuses on the internal analytical verification of a targeted microarray-based cfDNA test to ensure its reliability for detecting this critical deletion.
Study Design
This poster abstract describes the internal analytical verification process for a targeted microarray-based cell-free DNA test designed to detect the 22q11.2 deletion. No specific details regarding the study design, sample size, methodology, or assays used for the verification were provided in the abstract. The focus was on the process of validating the test's performance characteristics, rather than reporting specific experimental results.
Why It Matters
Accurate and reliable non-invasive prenatal screening for 22q11.2 deletion syndrome is crucial for early diagnosis and informed decision-making for expectant parents. The internal analytical verification of a targeted microarray-based cell-free DNA test signifies a critical step towards its clinical utility. Such rigorous validation ensures that the test provides dependable results, potentially reducing the need for more invasive diagnostic procedures like amniocentesis or chorionic villus sampling, which carry inherent risks. While specific performance metrics are not detailed, the emphasis on verification underscores the commitment to developing robust and trustworthy prenatal diagnostic tools.
22q11.2 deletion
digeorge syndrome
cell-free dna
nipt
prenatal diagnosis
genetic testing